MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Organization & Developments: Intercept
Parents
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Children
2014: Intercept Ends Roller Coaster Weekend With Phase 3 Victory
2014: Intercept Shares Skyrocket After Liver Drug Nails Mid-Stage Study (2014)
2014: Intercept shares soar after liver disease drug meets main goal_medcitynews (2014)
2014: What Biotech Pros Will Be Chirping About at JP Morgan This Week (2014)
2015: Intercept Pharma Dips As Analyst Doubts NASH Market ICPT RPTP GALT
2015: Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis
2017: Adding Intercept Pharmaceuticals As The Next Investment - Intercept Pharmaceuticals (NASDAQ:ICPT)
2017: VA_65--Intercept Pharmaceuticals, Inc Award Effective 1-15-2017 VA/FSS Contract Award under FSS Schedule 65IB
2018: Intercept Pharmaceuticals (ICPT)_seekingalpha.com
2018: Intercept Pharmaceuticals: Buyout Speculation Stokes Shares - Intercept Pharmaceuticals (NASDAQ:ICPT)
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: Intercept And Obeticholic Acid In NASH: Singing The Blues_seekingalpha.com
2019: Intercept's Upcoming NASH Data Is A Major Pivotal Point For Success - Intercept Pharmaceuticals (NASDAQ:ICPT)
2019: This Biotech (Intercept) Popped After Its Rival Crashed 76% On A Scrapped Test (Cymabay)_www.investors.com
2020: Another NASH delay for Intercept frustrates investors, shares wilt – Endpoints News
2020: FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines – Endpoints News
2020: Intercept Pharma to Cut 170 Employees in Wake of CRL for NASH Treatment
2022: Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patient
2022: Intercept Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentatio_seekingalpha.com
2022: Intercept Pharmaceuticals: Trying Time_seekingalpha.com
2022: Intercept Pharmaceuticals' Q3 Call Points To Progress In Revenues, Pipeline_ seekingalpha.com
2022: Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH_seekingalpha.com
2023: Intercept (ICPT) Targets Pivot To Profitability After NASH CRL
2023: Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
2023: Intercept to abandon NASH research, lay off staff after FDA drug rejection
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases
Jumps
*Key People: Intercept
Finance & Acquisitions: Intercept